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Abstract
Background: Prospective, population-based study of an 8-year follow up.
To determine the direct cost of diabetic retinopathy [DR], evaluating our screening programme and the cost of treating
DR, focusing on diabetic macular oedema [DMO] after anti-vascular endothelial growth factor [anti-VEGF] treatment.
Methods: A total of 15,396 diabetes mellitus [DM] patients were studied. We determined the cost-effectiveness of our
screening programme against an annual programme by applying the Markov simulation model. We also compared the
cost-effectiveness of anti-VEGF treatment to laser treatment for screened patients with DMO.
Results: The cost of our 2.5-year screening programme was as follows: per patient with any-DR, €482.85 ± 35.14; per
sight-threatening diabetic retinopathy [STDR] patient, €1528.26 ± 114.94; and €1826.98 ± 108.26 per DMO patient.
Comparatively, an annual screening programme would result in increases as follows: 0.77 in QALY per patient with any-
DR and 0.6 and 0.44 per patient with STDR or DMO, respectively, with an incremental cost-effective ratio [ICER] of €1096.
88 for any-DR, €4571.2 for STDR and €7443.28 per DMO patient. Regarding diagnosis and treatment, the mean annual
total cost per patient with DMO was €777.09 ± 49.45 for the laser treated group and €7153.62 ± 212.15 for the anti-VEGF
group, with a QALY gain of 0.21, the yearly mean cost was €7153.62 ± 212.15 per patient, and the ICER was €30,361.
Conclusions: Screening for diabetic retinopathy every 2.5 years is cost-effective, but should be adjusted to a patient's
personal risk factors. Treatment with anti-VEGF for DMO has increased costs, but the cost-utility increases to 0.21 QALY per
patient.
Keywords: Diabetic retinopathy, Diabetic macular oedema, Telemedicine, Cost of diabetic macular oedema, Cost of
diabetic retinopathy screening
Background
Diabetes mellitus [DM] is defined as a group of meta-
bolic diseases whose common feature is an elevated
blood glucose level [hyperglycaemia]. DM is a major
health problem worldwide; by 2010 more than 200 mil-
lion people had been diagnosed with diabetes and is
predicted to increase by 62 % over the period 1995 to
2025 [1]. Diabetic retinopathy [DR] is DM microangiop-
athy in the retina, which is the most common cause of
blindness in Europe [2]. To diagnose DR, the use non-
mydriatic fundus retinography and telemedicine [3]. A
screening programme obviously brings with it a cost to
the public health system [4] that depends on the number
of patients diagnosed with DR and the frequency of
screening. The expansion of screening programmes that
can diagnose patients with further ocular complications,
such as diabetic macular oedema [DMO] has brought
with it an increase in the overall cost of treatment. In
the present study, we determine the direct cost of DR to
our Health Care Area [HCA] between 2007 and 2014,
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including screening and the cost of diagnosis and treat-
ment of those patients who had DR and DMO, focusing
on the impact of that cost and the cost of the more re-
cent anti-VEGF treatment.
Methods
A population of 15,396, Caucasian, DM patients,
which is 86.53 % [15,396/17,792] of all DM patients
in our HCAs, were evaluated over an 8-year follow-
up period. Our population is homologous with other
areas in Spain.
Study design
A prospective, population-based study, conducted from
1st January 2007 to 31st December 2014. All diabetes pa-
tients screened annually within this period were in-
cluded in the study.
The inclusion criteria were: patients with diabetes melli-
tus type 1 or 2 referred to our HCAs, the screening
programme include the detection of DM patients by Fam-
ily Physicians, who send the patients to non-mydriatic
fundus camera unit, patients with HbA1c >7 %, insulin
treatment or DM duration >10 years, are focused as high
risk patients.
The exclusion criteria were: patients with other spe-
cific types of diabetes, those with gestational DM and
patients with DR who live outside our HCA.
Methods
We evaluated the cost of visits, examinations and in-
terventions carried out for each patient during the 8-
year follow-up. The classification used in the present
study, taking into account an eye with a high level of
DR, is: [i] no diabetic retinopathy [No-DR], [ii] any
diabetic retinopathy [level 20 to 35 of ETDRS] [any-
DR], [iii] sight-threatening diabetic retinopathy, de-
fined as level 43 retinopathy or worse by the ETDRS
[STDR], and/or [iv] sight-threatening maculopathy [STM].
DMO was classified as 'extrafoveal' or 'clinically significant
[CSMO]' according to the ETDRS classification.
Statistical methods
For the cost analysis, we used the Markov model with
TreeAge Pro 6.0 statistical software. The sensitivity of
our study was 90.2 % for DR, and the specificity was
98.6 %. Costs were standardized using data published by
the Health Department of Catalonia [CatSalut] and the
costs of pharmaceuticals, surgery material [5] and health
staff spending of Hospital Universitari Sant Joan. In the
present study we determined only direct costs. An an-
nual 3 % discount rate was applied for future costs and
utilities, consistent with the standard UK approach. The
analysis was calculated in three steps: [i] a comparison
of the cost of a 2.5-year screening programme with the
cost of an annual programme, [ii] an evaluation of the
cost of diagnosis and treatment of DR at the hospital,
[iii] an analysis of the DMO treatment cost-utility, focus-
ing on the inclusion of anti-VEGF drugs.
Our DR screening programme was evaluated by a
cost-effectiveness study, comparing the current 2.5-year
programme to a theoretical annual programme. Quality-
adjusted life-years [QALYs] were used as the primary model
outcome measure, using visual acuity as related time-trade
off data for evaluating utility, and using life expectancy sta-
tistics for Spain in DM patients [78 years]. We also deter-
mined the incremental cost-effective ratio [ICER] in the
analysis of annual costs against the cost of our current 2.5-
year programme [6]. The rates of progression of DR is ac-
cording to the meta-analysis of Wong et al., [7].
The cost of DMO [only CSMO type] treatment with
anti-VEGF intravitreal drugs was evaluated by a cost-
utility study based on the QALYs gained [8], considering
the utility values most commonly accepted in the oph-
thalmology literature [8, 9]. We compare DMO patients
treated with laser [2007 to 2010] and patients treated
only by anti VEGF [2011 to 2014]. The comparison with
patients treated with laser takes into account only the
first eye treated. A descriptive statistical analysis of
quantitative data was made. We used the analysis of fre-
quency and percentage in each category. Differences be-
tween those included in the analyses were examined
using the two-sample tailed t-test to compare two vari-
ables or a one-way ANOVA as if we were comparing
more than two variables. Data evaluation and analysis
was carried out using SPSS 22.0 statistical software pack-
age and p < 0.05 was considered statistically significant.
Results
All 15,396 patients were screened, with a mean follow
up of 3.18 ± 1.11 times for each patient over the 8 years.
Screening took place every 2.5 years. The mean of the
number of patients screened annual was 5507 ± 491.9
[5089, 6337], a mean percentage of 35.09 %. The whole
sample included more males [m = 8168, f = 7227], which
does in fact reflect the prevalence of diabetes in the
population as a whole. The mean age of patients without
DR was 65.66 ± 12.23 years, patients with any DR was
63.91 ± 11.85 years, patients with sight threatening dia-
betic retinopathy [STDR] was 61.48 ± 10.91 years and
patients with DMO was 60.67 ± 10.37 years.
Table 1 shows the number of patients screened annu-
ally, and the incidence of DR at its different levels. The
8-year incidence of any-DR was 24.12 %, with an annual
mean incidence value of 8.37 ± 2.19 % [8.09–8.99 %]. For
STDR, the 8-year incidence was 7.59 % with an annual
mean incidence value of 2.64 ± 0.15 % [2.48–2.88 %],
and for DMO it was 6.36 % with an annual mean inci-
dence value of 2.19 ± 0.18 % [2–2.49 %].
Romero-Aroca et al. BMC Ophthalmology  (2016) 16:136 Page 2 of 7
Analysis of cost of DR screening
The cost of screening remained stable from 2007 to
2014 [Table 2]. The mean cost was € 223,568 ± 20,956
[€201,840 to € 258,480]. Statistical analysis using the
two-sample tailed t-test showed the differences in the
total cost of screening were not significant [p = 0298;
95 % CI 201,802–237,717]. The annual mean screening
cost per patient was € 40.53 ± 1.21. For a patient with
any-DR the mean annual cost was € 482.85 ± 35.14; the
annual mean cost of screening for a patient with STDR
was € 1528.26 ± 114.94; and the mean annual cost for a
patient with only DMO was € 1826.98 ± 108.26.
Table 3 shows the cost of screening annually com-
pared with the current programme. For a patient with
any DR, the cost would be €482.32 with a QALY of
11.28. Screening every year would result in an in-
crease of 0.77 in the annual QALY but at a cost of
€1347.89. For a patient with STDR or DMO, the an-
nual QALY would increase to values of 0.6 and 0.44
respectively. The ICER would increase the cost to
€1096.88 for any-DR, € 4571.2 for STDR and €
7443.28 for DMO patients.
Cost of DR diagnosis and treatment
The mean annual cost of diagnosis and treatment of pa-
tients with any-DR was €94,902 ± 19,576 [€77,995 to
€128,359], with a mean cost per patient of €285.18 ±
21.61. Table 4 shows the cost of diagnosis and treatment
of patients with DR by years, and Table 5 shows the ana-
lysis of the cost of diagnosis and treatment of patients
with DR.
Analysis of cost-utility of diagnosis and treatment of
DMO patients
Table 6 shows the total cost of patients with DMO over
the 8 years. The group of patients treated by anti-VEGF
drugs [2011 to 2014] was given an average of 5.7 injec-
tions the first year, 4.7 injections the second year and 2.9
the third year.
There were two groups of patients treated for CSMO:
– Group 1 treated by grid or focal laser [2007 to 2010]
show a mean annual cost of €67,024 ± 8102€
[€56,880 to €75,317] or €777.09 ± 49.45 per patient.
– Group 2 treated by anti-VEGF intravitreal injections
[2011 to 2014] show a mean annual cost of
€545,464 ± 69,128 [€459,384 to € €626,264] or
€7153.62 ± 212.15 per patient per year.
For group 1, the mean VA gain after laser treatment
was 0.68 ± 1.78 [−11 to 6] letters, and the mean gain in
VA for group 2 increased to 6.84 ± 3.22 [0 to 10] letters.
The mean cost per patient of total DMO treatment
during a 3 year follow up, was €17791.99, which is from
data only available for patients recruited between 2007
to 2013.
Table 1 Cases of diabetic retinopathy
2007 2008 2009 2010 2011 2012 2013 2014
Patients screened 5027 32.65 % 4989 32.40 % 5312 34.50 % 5367 34.86 % 5276 34.22 % 6337 41.16 % 5623 36.52 % 6125 39.78 %
Annual incidence of any DR 407 8.09 % 402 8.06 % 428 8.06 % 432 8.05 % 426 8.07 % 556 8.77 % 502 8.92 % 551 8.99 %
Mild-DR 349 6.94 % 344 6.89 % 368 6.92 % 377 7.02 % 363 6.88 % 441 6,96 % 397 7.06 % 432
Moderate-DR 33 0.65 % 32 0.64 % 33 0.62 % 31 0.58 % 33 0.62 % 64 1 % 67 1.14 % 7.05 %
Severe-DR 24 0.48 % 26 0.52 % 26 0.49 % 24 0.48 % 30 0.57 % 47 0.74 % 43 0.76 % 65
Proliferative-DR 1 0.02 % 0 1 0.02 % 0 0 4 0.06 % 5 0.08 % 1.06 %
Total-DRa 407 8.09 % 402 8.06 % 428 8.06 % 432 8.05 % 426 8.07 % 556 8.77 % 502 8.92 % 551 8.99 %
Sight-Threatening DR 131 2.6 % 125 2.5 % 132 2.48 % 134 2.49 % 141 2.67 % 170 2.68 % 162 2.88 % 174 2.84 %
Extrafoveal-DMO 39 [0.75 %] 35 [0.72 %] 43 [0.84 %] 37 [0.69 %] 38 [0.72 %] 58 [0.92 %] 48 [0.86 %] 39 [0.75 %]
CSMEc 65 [1.25 %] 66 [1.25 %] 69 [1.27 %] 77 [1.43 %] 72 [1.36 %] 92 [1.44 %] 87 [1.54 %] 65 [1.25 %]
Total-DMOb 104 2.00 % 101 2.02 % 112 2.11 % 114 2.12 % 110 2.08 % 150 2.36 % 135 2.40 % 153 2.49 %
DRa diabetic retinopathy, DMOb diabetic macular oedema, CSMOc clinical significant macular oedema
Table 2 Direct cost of screening of patients with DR




















Total cost of screening €203,240 €201,840 €214,640 €217,080 €213,480 €258,480 €229,560 €250,224 p = 0,298
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For the cost-utility analysis in DMO patients, we used
the utility value according Brown et al. [8] for anti-
VEGF drug differences with laser, and only the first year
of treatment was taken into account. By mean age in
DMO in the population [60.67 ± 10.37 years], we consid-
ered a further 17.33 years life expectancy in a Spanish
population with DM [78 year], and the QALY gain value
was 0.21. The yearly mean cost per patient was
€7153.62 ± 212.15 per QALY, and the ICER was €30,361
per QALY.
Discussion
In the present study, there are two key points to the cost
of DR, the cost of screening and the cost of the DMO
treatment, which has increased hugely since the intro-
duction of anti-VEGF drugs. When screening for DR,
retinography is the method recommended by scientific
societies because it has proven to be cost effective
[10, 11]. However, the present study shows that an
8.37 ± 2.19 % detection rate of DR per year [463 ±
63.61 patients] has a total cost of €223,568 ± 20,956.
Furthermore, the annual percentage of patients with
DR whose condition can lead to poor vision or blind-
ness [STDR], is 2.64 ± 0.15 % [an average of 146.1 ±
19.45 patients] and DMO is detected in 2.19 ± 0.18 %
of patients [122.4 ± 20.65 patients]. If these patients
go on to develop poor vision or blindness it will rep-
resent a significant cost to society, so early detection
is of great cost benefit [12].
Telemedicine screening for DR has been evaluated in
different studies. Rein et al. in 2011 [13] demonstrated
that a biannual eye examination by an ophthalmologist
is more cost-effective than annual telemedicine. Exami-
nations every 2 years might be cost-effective after one or
more normal results and in a population with well-
controlled type 2 diabetes [14]. There was essentially no
risk of developing significant retinopathy within 3 years
of a normal examination result [15]. The American Dia-
betes Association [2016] position statement concluded
that if there is no evidence of DR in one or more eye
examinations, then controls every 2 years can be consid-
ered adequate. If DR is present, subsequent examina-
tions for patients with type 1 and type 2 DM should be
repeated annually by an ophthalmologist or optometrist
[16]. The present study demonstrates that for our popu-
lation, a screening interval of 2.5 years is cost-effective,
and annual screening would not improve the management
of diabetes patients. For patients with STDR or DMO the
results are not so conclusive, but these patients have poor
vision, and therefore come for screening earlier than other
patients with mild-DR. Furthermore, these patients have
worse metabolic status, which requires more attention
from their family doctor. It would seem sensible, there-
fore, to focus screening on patients whose characteristics
can be defined as high-risk for developing DR, and we
need to identify the patients who need more attention.
The present study also focused on the diagnosis and
treatment of patients with diabetic retinopathy. Results
show that treatment costs increased from €199.66 ±
19.92 in 2007 to €232.95 ± 21.48 in 2014. This increase
can be explained by an increase in more severe forms of
DR in recent years, related to poor metabolic control, as
we described previously [17].
Finally, the study of DMO treatment costs was focused
on the new intravitreal drugs. The introduction of anti-
VEGF drugs for treatment of DMO [18] has been re-
placing laser treatment as the gold standard for DMO
since 2011 according to ETDRS protocol [19] and for
non-responsive DMO, we have recently been using cor-
ticoids, [20, 21]. In the present study, we only included
Table 3 Statistical analysis of cost of screening annually against the current 2.5 years
Time of screening Cost per patients diagnosed QALY ICER annual against 2.5 years QALY increment
Any DR 1 year €1347.89 12.05 €1096.88 0.77
2.5 years €482.32 11.28
STDR 1 year €4270.98 11.27 €4571.2 0.60
2.5 years €1528.26 10.67
DMO 1 year €5099.91 11.87 €7443.28 0.44
2.5 years €1824.82 11.43
Table 4 Direct cost of diagnosis and treatment of patients with DR
Year 2007 2008 2009 2010 2011 2012 2013 2014 Significance
Total cost of diagnosis of DR patients €62,347 €64,140 €63,822 63,702
€
€66,518 €67,164 €677,512 €667,717 p = 0.418
Total cost of DR diagnosis and treatment* €81,262 €79,886 €82,334 €77,995 €85,598 €107,209 €116,574 €128,359 P < 0.001*



















Total cost of DR diagnosis and treatment. *The significance is due to anti-VEGF treatment being included
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anti-VEGF drugs because non-responsive cases appeared
later than our study period. Table 6 shows the cost im-
pact of DMO treatment by these drugs. It shows an ex-
ponential increase in the mean cost before 2011 of
€67,024 ± 8102 to €545,464 ± 69,128 after 2011. Statis-
tical analysis shows that anti-VEGF drugs are more ef-
fective than laser treatment for DMO patients, with an
increase in visual acuity of 6.84 ± 3.22 letters in anti-
VEGF treated patients against 0.86 ± 0.78 letters in the
group treated with laser. This is an increase of 1.23 lines
in ETDRS letters similar to the increase in VA observed
in the READ 2 study, [22]. The QALY gain value was
0.21, a value similar to the 0.17 QALY gain in the
Mitchell et al. study [23]. That study applied its model at
15 years from a baseline of 63 years whereas our model is
based on 17 years with a mean patient age of 60 years. Ap-
plying the 15-year model to our results predicts a 0.18
QALY gain value, and for a younger population the anti-
VEGF cost-effectiveness might be higher because of their
longer rest-of-life expectancy.
The ICER of €30,361 per QALY gained relative to laser
therapy is lower than the willingness-to-pay [WTP] that
is required to be considered cost-effective by the
National Institute for Health and Care Excellence
[€38,460 or £30,000].
We can conclude, then, that treatment with anti-
VEGF drug is cost-useful. Despite the present study be-
ing limited to the first year treatment follow up, the
increase in VA remains stable, as found in other studies
[24]. A difference worth noting is that in the first year
the treatment, a mean of 5.7 injections of anti-VEGF per
patient is fewer than in other studies such as RESTORE
[23], with 10 injections the first year, or the RISE and
RIDE clinical trials with 12 injections [25].
A potential weakness of our study is the use of medical
record diagnoses and treatment from an integrated
Table 5 Direct cost of diagnosis and treatment per patient with DR
Direct cost of
screening programme
to detect a patient
Direct cost of diagnosis
per patient
Yearly direct cost of
treatment per patient
Yearly direct cost of
follow up per patient
Any DR €482.32 ± 35.14 €100.51 ± 23.75 €184.67 ± 19.47 €288.15 ± 37.93
Sight threatening DR €1528.26 ± 114.94 €167.91 ± 7.69 €2191 ± 15.51 €441.37 ± 10.83
DMO €1824.82 ± 108.26 €132.24 ± 8.17 €777.09 ± 49.45a €509.42 ± 20.28a
€7153.62 ± 212.15b €473.56 ± 62.69b
Mild DR €443 ± 61.21 €79.45 ± 8.05 €139.27 ± 27.88 €145 ± 18.65
Moderate DR €4995,93 ± 468,29 €108.12 ± 31.37 €5319.01 ± 1307.04 €448.76 ± 79.35
Severe DR €7452,26 ± 698,53 €175.23 ± 48.21 €7970,93 ± 897.45 €475.13 ± 77.65
Proliferative €94,332,48 ± 8842,19 €244.97 ± 87.16 €12177.74 ± 1027.22 €995.78 ± 97.47
aTreatment or follow up of DMO patients treated with laser, bTreatment of DMO patients treated with anti-VEGF
Table 6 Cost of diagnosis, treatment and follow up of diabetic macular oedema
Year 2007 2008 2009 2010 2011 2012 2013 2014
Number of patients with DMO 103 101 112 114 110 150 135 153
Cost of DMO diagnosis [Visit + FA + OCT] €15,686 €15,382 €17,024 €17,328 €16,720 €16,752 €14,328 €16,238
Cost of grid laser treatment [Treatment + follow
visits and OCT /FA] DMO treated with laser
€12,750 €11,250 €12,600 €13,050 No cases No cases No cases No cases
Cost of 1 year follow up € 51,680 € 48,120 € 51,072 € 52,896 No cases No cases No cases No cases
Cost of Anti-VEGF treatment [Treatment + follow
visits and OCT /FA] DMO
Intravitreal Anti-VEGF
No cases No cases No cases No cases €389,327 €437,250 €472,929 €518,870
Cost of 1 year follow up No cases No cases No cases No cases €39,510 €47,040 €48,048 €54,824
Cost of vitrectomy treatment [Treatment + follow
visits and OCT /FA] DMO
Vitrectomy
€5996 €3669 €5628 €6851 €4037 €6851 €3315 €8442
Cost of 1 year follow up €2140 €1480 €2080 €2520 €1490 €2480 €1664 €3328
Treatment DMO cost €56,880 €64,519 €71,380 €75,317 €459,384 €534,251 €561,956 €626,264
Total of the DMO cost €72,566 €79,901 €88,404 €92,645 €476,104 €551,003 €576,284 €642,503
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health care delivery system. The results of the present
study do not represent all of the ophthalmology service
costs of diabetes patients, because only patients referred
from the screening programme have been evaluated ra-
ther than other patients from other hospitals. Weak-
nesses, also include the use of a screening programme
can reduce the number of patients diagnosed with severe
forms of DR, also the severity scale could vary if we use
wide field image techniques, and the number of patients
with STDR can increase. Finally, the number of patients
who developed proliferative DR is small and can bias the
statistical analysis.
The DMO treatment only takes into account the first
treated eye, that which has a more advanced degree of
oedema. In addition, the limitation of a 2-year follow up
of each patient can reduce the total cost effectiveness
for DMO. One strength is that it is a prospective,
population-based study, representative of the Spanish
population and representative of the standard man-
agement of patients with diabetic retinopathy, as op-
posed to studies that use the Markov or Monte Carlo
models that simulate hypothetical cohorts [14, 26].
Conclusion
A screening programme of 2.5 years by telemedicine is
cost effective. The cost of screening can be reduced by
better selection of time lapse individually tailored to
each patient based on their personal risk factors. The
cost of DMO increased after anti-VEGF drugs were in-
troduced, but is cost-useful.
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